The Combination of Venetoclax and Ibrutinib Is Effective in Relapsed/Refractory T-Prolymphocytic Leukemia and Influences BCL-2-Family Member Dependencies
Hematological Oncology - United Kingdom
doi 10.1002/hon.161_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley